PURPOSE: Computed tomography (CT) or magnetic resonance imaging (MRI) guided brachytherapy provides high @entity5 control rates in @entity157 ( @entity157 ) and colorectal liver metastases. In contrast to thermal ablation methods such as radiofrequency ablation (RFA), much less restrictions apply with respect to @entity5 location or size. In this study, we determined the efficacy and safety of CT- or MRI-guided brachytherapy in @entity320 . MATERIAL AND METHODS: Fifty-two metastases of @entity320 in 14 @entity1 were included in this retrospective study. @entity5 control and safety were evaluated as primary and secondary endpoints. Furthermore, we evaluated overall survival and progression free survival. @entity5 locations were liver (n = 31), lung (n = 15), adrenal (n = 3), lymph nodes (n = 2), and kidney (n = 1). Treatment planning was performed using three-dimensional CT or MRI data acquired after percutaneous applicator positioning under CT or open MRI guidance. Subsequently, single fraction @entity1168 ( @entity1168 ) brachytherapy was applied using a (192)Iridium source. Clinical and cross-sectional follow-up were performed every 3 months post intervention. RESULTS: The median diameter of treated lesions was 1.5 cm (range: 0.7-10 cm). Doses between 15 and 20 Gy were applied (median dose: 19.9 Gy). The mean irradiation time ranged between 7-45 minutes. After treatment, there was one @entity1 with a @entity255 . After a median follow up of five months, the median local @entity5 control was 90%. The median overall survival of the @entity1 was 8 months. The median progression free survival of the @entity1 was 6 months. CONCLUSIONS: Image-guided @entity1168 brachytherapy is a safe and effective treatment procedure in metastatic @entity320 .

Efficacy and safety of image-guided interstitial single fraction XXXX brachytherapy in the management of metastatic @entity320 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumor', 'Local tumor'] @entity255 :: ('MESH:D002761', 'Disease') :: ['cholangitis'] @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'hepatocellular carcinoma'] @entity1168 :: ('MESH:D001919', 'Disease') :: ['HDR', 'high-dose-rate'] @entity320 :: ('MESH:D008545', 'Disease') :: ['metastatic melanoma', 'malignant melanoma']
@entity1168 :: (MESH:D001919,Disease) :: ['high-dose-rate']
